Beckman to Acquire Agencourt For Up to $140M; Plans New 'Personal Genomics' Spin-Off
Beckman Coulter intends to purchase Agencourt Bioscience for up to $140 million in cash, the companies said last week.
Beckman plans to acquire all of Agencourt's outstanding stock for $100 million in cash and make up to $40 million in contingent payments through 2007. Following the acquisition, which is expected to close near the end of May, Agencourt will become a wholly owned subsidiary of Beckman, and will remain based in Beverly, Mass.
Agencourt's management team and its workforce of about 100 will remain in place, according to the company.
In addition, Agencourt and Beckman plan a spin-off, to be called Agencourt Personal Genomics, which will develop a "sequencing-by-synthesis" approach for sequencing individuals' genomes.
PerkinElmer Life and Analytical Sciences Revenue Up 6 Percent in Q1
PerkinElmer last week reported a 6-percent rise in first-quarter 2005 revenues from its Life and Analytical Sciences unit, and revenue growth for the quarter of 6 percent for the company overall.
PerkinElmer Life and Analytical Sciences revenues for the first three months of 2005 increased to $264.8 million from $249.2 million year over year. The company attributed the growth to "strong growth in genetic screening, medical imaging, environmental and service."
The unit's other businesses include biopharma and biotech imaging.
The company's overall revenues for the quarter were $416.3 million, up $23.6 million from first-quarter 2004 revenues of $392.6 million.
Net income in the first quarter rose from $13.2 million, or $.15 per share, in 2004 to $19.8 million, or $.10 per share, in 2005.
R&D spending in the period grew to $23.6 million from $20.2 million in the similar quarter of 2004.
As of April 3, the company reported cash and cash equivalents of $184.2 million, with total current assets of $743.2 million.
Becton Dickinson Said Fiscal Q2 Revenues Climb 9 Percent; Diagnostic Segment Leads Growth
Becton Dickinson today reported $1.4 billion in total fiscal second-quarter revenues, a 9-percent increase from the same quarter one year ago.
Revenues were up across BD's Medical, Diagnostics, and Biosciences segments, and BD attributed further revenue increase to foreign currency translation, particularly the euro.
Diagnostics led the growth with a 12-percent increase over the comparable period last year, while biosciences and medical grew by 9 percent and 8 percent, respectively.
R&D spending in the quarter rose to $66 million from $60.2 million in the second quarter of 2004.
Net earnings increased to $188 million, or $.74 per basic share, from $165 million, or $.65 per share, during the second quarter of FY'05.
Cash and cash equivalents were not provided in the statement.
Ikonisys and Cancer Research Technology Ink Automated Microscopy; Rare Cell Detection Agreement
Ikonisys said last week that it has signed an agreement with Cancer Research Technology granting Ikonisys exclusive rights to reagents for use with Ikonisys' Celloptics technology platform.
The agreement also grants Ikonisys a worldwide exclusive option to commercialize monoclonal antibodies and other reagents specific for detecting circulating tumor cells using the Ikoniscope and IkoniLAN robotic microscopy platforms, the companies said.
Furthermore, Ikonisys will sponsor an R&D project at the Cancer Research UK Cancer and Immunogenetics Laboratory at the Weatherall Institute of Molecular Medicine in Oxford, UK, the companies said.
Affymetrix Licenses Caliper's Microfluidics Technology
Caliper Life Sciences has licensed an undisclosed number of its microfluidics patents to Affymetrix for use in microarray technology, the companies said last week.
Under the non-exclusive agreement, Affymetrix may use the technology in its GeneChip products for research, diagnostics, and applied genomics applications in exchange for an upfront licensing fee and royalties on future products. The license excludes use of the technology to separate nucleic acids as a quality control step.
This is Caliper's second licensing deal since it began to outlicense its intellectual property on microfluidics. In January, Predicant Biosciences licensed Caliper's technology for use in the analysis of proteins by mass spectrometry.